Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma

Research output: Contribution to journalLetter

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this